dc.creatorBenzaken, Adele Schwartz
dc.creatorSabidó, Meritxell
dc.creatorPedroza, Valderiza
dc.creatorVasquez, Felicien
dc.creatorAraújo, Adauto José Goncalves de
dc.creatorPeeling, Rosanna W
dc.creatorMaynaud, Phillippe
dc.date2019-08-26T13:12:58Z
dc.date2019-08-26T13:12:58Z
dc.date2008
dc.date.accessioned2023-09-26T22:15:38Z
dc.date.available2023-09-26T22:15:38Z
dc.identifierBENZAKEN, Adele Schwartz et al. Field evaluation of the performance and testing costs of a rapid point-of-care test for syphilis in a red-light district of Manaus, Brazil. Sexually Transmitted Infections, v. 84, n. 4, p. 1-6, 2008.
dc.identifier1368-4973
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/35060
dc.identifier10.1136/sti.2008.030411
dc.identifier1472-3263
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8876968
dc.descriptionOBJECTIVES: To assess the performance, usefulness and cost of a rapid treponemal antibody assay (VisiTect Syphilis) to detect syphilis in high risk populations. METHODS: People who attended STI clinics in Manaus, Brazil, were screened for syphilis using the fluorescent treponemal antibody absorption (FTA-Abs) test and a non-treponemal test (Venereal Diseases Research Laboratory (VDRL)), and for HIV. Finger prick blood samples were tested with VisiTect Syphilis. The rapid test was evaluated against the reference FTA-Abs and for its usefulness in detecting active syphilis (FTA-Abs and VDRL positive). Operational performance was assessed through providers' and patients' interviews. An economic evaluation was conducted from the provider's perspective. RESULTS: 510 patients (60% men) were enrolled, of whom 13 (2.5%) were HIV-1 seropositive. Syphilis prevalence (FTA-Abs) was 18% and active syphilis prevalence was 7.5%. 11% (57/506) of samples were positive by VisiTect. The sensitivity, specificity, positive and negative predictive values of VisiTect Syphilis were 57% (95% CI 45.8 to 66.7), 99% (95% CI 97.0 to 99.6), 91% (95% CI 80.0 to 96.7) and 91% (95% CI 88.0 to 93.5), respectively. VisiTect Syphilis identified 79% (30/38) of active syphilis cases. The cost per case of syphilis was $16.8 for VDRL, $33.2 for low cost and $56.3 for high cost VisiTect Syphilis; the cost per case of active syphilis was $21.3, $57.5 and $97.6, respectively. Patients identified finger prick pain and preference for venous blood collection as minor barriers to test use. CONCLUSION: VisiTect Syphilis had low sensitivity in field use and was less cost effective than conventional VDRL. However, rapid and correct identification of a high proportion of active syphilis cases combined with operational characteristics suggest a role in high risk populations.
dc.formatapplication/pdf
dc.languageeng
dc.publisherBritish Association of Sexual Health and HIV
dc.rightsopen access
dc.subjectSyphilis
dc.titleField evaluation of the performance and testing costs of a rapid point-of-care test for syphillis in a red-light district of Manaus, Brazil
dc.typeArticle


Este ítem pertenece a la siguiente institución